Cartesian Therapeutics (RNAC) Total Debt (2015 - 2023)

Cartesian Therapeutics (RNAC) has 9 years of Total Debt data on file, last reported at $28.3 million in Q4 2023.

• Total Debt for Q4 2023 came in at $28.3 million, up 59.15% year-over-year; the trailing twelve-month figure through Dec 2023 was $28.3 million (up 59.15% YoY), and the FY2023 annual result was $28.3 million, up 59.15% from the prior year.
• Total Debt improved to $28.3 million in Q4 2023 per RNAC's latest filing, from $24.0 million in the prior quarter.
• Over five years, Total Debt peaked at $28.3 million in Q4 2023 and troughed at $14.8 million in Q2 2020.
• A 5-year average of $23.1 million and a median of $24.8 million in 2020 frame the typical range for Total Debt.
• The sharpest annual moves came in 2020 and 2021: Total Debt plunged 31.16% in 2020, then soared 70.04% in 2021.
• A 5-year view of Total Debt shows it stood at $18.9 million in 2019, then surged by 31.15% to $24.8 million in 2020, then rose by 3.39% to $25.6 million in 2021, then sank by 30.62% to $17.8 million in 2022, then surged by 59.15% to $28.3 million in 2023.
• Business Quant data shows RNAC's Total Debt at $28.3 million in Q4 2023, $24.0 million in Q2 2023, and $26.4 million in Q1 2023.